JP2006514607A - 長時間持続性ナトリウム排泄増加性ペプチド誘導体 - Google Patents

長時間持続性ナトリウム排泄増加性ペプチド誘導体 Download PDF

Info

Publication number
JP2006514607A
JP2006514607A JP2004523679A JP2004523679A JP2006514607A JP 2006514607 A JP2006514607 A JP 2006514607A JP 2004523679 A JP2004523679 A JP 2004523679A JP 2004523679 A JP2004523679 A JP 2004523679A JP 2006514607 A JP2006514607 A JP 2006514607A
Authority
JP
Japan
Prior art keywords
absent
ala
arg
seq
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004523679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514607A5 (https=
Inventor
ドミニク ピー． ブリドン，
ピーター バキス，
ジュリー カレッテ，
フランス レクレア，
ロジャー レガー，
マーティン ロビタイル，
Original Assignee
コンジュケム，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンジュケム，インコーポレーテッド filed Critical コンジュケム，インコーポレーテッド
Publication of JP2006514607A publication Critical patent/JP2006514607A/ja
Publication of JP2006514607A5 publication Critical patent/JP2006514607A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
JP2004523679A 2002-07-31 2003-07-29 長時間持続性ナトリウム排泄増加性ペプチド誘導体 Pending JP2006514607A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40019902P 2002-07-31 2002-07-31
US40041302P 2002-07-31 2002-07-31
PCT/CA2003/001097 WO2004011498A2 (en) 2002-07-31 2003-07-29 Long lasting natriuretic peptide derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009273992A Division JP2010047614A (ja) 2002-07-31 2009-12-01 長時間持続性ナトリウム排泄増加性ペプチド誘導体

Publications (2)

Publication Number Publication Date
JP2006514607A true JP2006514607A (ja) 2006-05-11
JP2006514607A5 JP2006514607A5 (https=) 2006-09-07

Family

ID=31191354

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004523679A Pending JP2006514607A (ja) 2002-07-31 2003-07-29 長時間持続性ナトリウム排泄増加性ペプチド誘導体
JP2009273992A Pending JP2010047614A (ja) 2002-07-31 2009-12-01 長時間持続性ナトリウム排泄増加性ペプチド誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009273992A Pending JP2010047614A (ja) 2002-07-31 2009-12-01 長時間持続性ナトリウム排泄増加性ペプチド誘導体

Country Status (5)

Country Link
EP (1) EP1530588A2 (https=)
JP (2) JP2006514607A (https=)
AU (1) AU2003246500A1 (https=)
CA (1) CA2488348A1 (https=)
WO (1) WO2004011498A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008162987A (ja) * 2006-12-31 2008-07-17 Toshiko Koide 心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法
JP2014506584A (ja) * 2011-02-23 2014-03-17 マデライン ファーマシューティカルズ ピーティーワイ リミテッド うっ血性心不全を処置するための治療方法
JP2021073234A (ja) * 2015-05-29 2021-05-13 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬、外用剤および化粧料

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
DK1360202T3 (da) 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
WO2004022003A2 (en) 2002-09-06 2004-03-18 University Of South Florida Materials and methods for treatment of allergic diseases
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
AU2005227870A1 (en) 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
WO2006005140A2 (en) 2004-07-15 2006-01-19 The University Of Queensland Proteinaceous compounds and uses therefor
ES2363738T3 (es) * 2005-03-07 2011-08-12 Mondobiotech Ag Formulación de aviptadil.
WO2006108686A2 (en) * 2005-04-14 2006-10-19 Aic Bnp agonists
US20080227713A1 (en) * 2005-10-03 2008-09-18 Protter Andrew A Oxidized Human Bnp
WO2007127487A2 (en) 2006-04-28 2007-11-08 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
KR20080098216A (ko) * 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
US20100310561A1 (en) * 2007-06-06 2010-12-09 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
AP2009005091A0 (en) * 2007-07-06 2009-12-31 Theratechnologies Inc Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (ALPHA-MSH) and atrial natriuretic protein (ANP) and uses in hypertension andacute kidney injury
DE102010032482A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe zur Beeinflussung der natriuretischen Peptid-Rezeptoren A und B und deren Verwendung
WO2012013597A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
CN102286092B (zh) 2011-09-14 2014-01-01 深圳翰宇药业股份有限公司 利拉鲁肽的固相合成方法
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬
WO2024086680A2 (en) 2022-10-21 2024-04-25 Eli Lilly And Company Long-acting natriuretic peptides and uses thereof
CN116284329B (zh) * 2023-04-28 2023-12-08 成都奥达生物科技有限公司 一种长效利钠肽化合物
CN121717878A (zh) * 2024-12-02 2026-03-24 中山大学 一种用于npr-b靶向的超长效多肽及其在骨骼系统病症中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63501294A (ja) * 1985-11-05 1988-05-19 カリフォルニア・バイオテクノロジー・インク 心房性ナトリウム尿排泄亢進ペプチド類似化合物
JPH04500363A (ja) * 1989-05-24 1992-01-23 アボツト・ラボラトリーズ 心房ペプチド誘導体
JP2000191688A (ja) * 1985-11-05 2000-07-11 Scios Inc 心房性ナトリウム尿排泄亢進ペプチド類似化合物
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2000070665A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting anti-angiogenic peptides
WO2001017614A2 (en) * 1999-09-07 2001-03-15 Conjuchem, Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63501294A (ja) * 1985-11-05 1988-05-19 カリフォルニア・バイオテクノロジー・インク 心房性ナトリウム尿排泄亢進ペプチド類似化合物
JP2000191688A (ja) * 1985-11-05 2000-07-11 Scios Inc 心房性ナトリウム尿排泄亢進ペプチド類似化合物
JP2002167396A (ja) * 1985-11-05 2002-06-11 Scios Inc 心房性ナトリウム尿排泄亢進ペプチド類似化合物
JPH04500363A (ja) * 1989-05-24 1992-01-23 アボツト・ラボラトリーズ 心房ペプチド誘導体
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2000070665A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting anti-angiogenic peptides
WO2001017614A2 (en) * 1999-09-07 2001-03-15 Conjuchem, Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents
WO2001017568A2 (en) * 1999-09-07 2001-03-15 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008162987A (ja) * 2006-12-31 2008-07-17 Toshiko Koide 心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法
JP2014506584A (ja) * 2011-02-23 2014-03-17 マデライン ファーマシューティカルズ ピーティーワイ リミテッド うっ血性心不全を処置するための治療方法
JP2021073234A (ja) * 2015-05-29 2021-05-13 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬、外用剤および化粧料
JP2023096139A (ja) * 2015-05-29 2023-07-06 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬品、外用剤および化粧料
JP7604020B2 (ja) 2015-05-29 2024-12-23 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬品、外用剤および化粧料
JP2025032183A (ja) * 2015-05-29 2025-03-11 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬品、外用剤および化粧料

Also Published As

Publication number Publication date
WO2004011498A3 (en) 2004-06-24
CA2488348A1 (en) 2004-02-05
WO2004011498A2 (en) 2004-02-05
JP2010047614A (ja) 2010-03-04
AU2003246500A1 (en) 2004-02-16
EP1530588A2 (en) 2005-05-18

Similar Documents

Publication Publication Date Title
JP2006514607A (ja) 長時間持続性ナトリウム排泄増加性ペプチド誘導体
US20080199532A1 (en) Long Lasting Natriuretic Peptide Derivatives
JP4280070B2 (ja) 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
US7268113B2 (en) Long lasting growth hormone releasing factor derivatives
JP4115671B2 (ja) 長期間持続するインシュリン向性ペプチド
US7906482B2 (en) Anti-obesity agents
AU2002233089A1 (en) Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
AU2002233082A1 (en) Long lasting growth hormone releasing factor derivatives
ZA200106676B (en) Long lasting insulinotropic peptides.
HK1123312A (en) Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
AU2005218012A1 (en) Long lasting growth hormone releasing factor derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060719

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20071025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090810

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090929

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091021

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100416